The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|May 31, 2019
Collaboration Forms to Launch Medical Cannabis Working Group
Author(s)Pharmaceutical Technology Editors
Cannuba has announced that it is collaborating with an independent scientific body on drugs from the UK on the launch of a medical cannabis working group.
Advertisement
Cannuba, a medical cannabis research and production firm, has announced that it is collaborating with an independent scientific body on drugs from the United Kingdom on the launch of a medical cannabis working group.
In a May 28, 2019 press release, Cannuba stated its participation in the Drug Science Cannabis Working Group, which was officially launched at the Drug Science annual reception in the House of Lords on May 22, 2019. The working group, which includes drug science experts, patient representatives, policy makers, and other industry partners, will develop approaches to improving patient access to medical cannabis in the UK.
“Cannuba is both honored and excited to be a part of the Drug Science Working Group. We will be working alongside leading industry professionals to assist with integral research,” said Rob James, CEO of Cannuba. “With the right due diligence in place, our aim is to help people all over the UK gain access to life-changing medical products. This is a unique and privileged opportunity and puts Cannuba at the very forefront of meaningful scientific research.”
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement